| Original language | English |
|---|---|
| Pages (from-to) | 849-851 |
| Number of pages | 3 |
| Journal | European Urology |
| Volume | 74 |
| Issue number | 6 |
| Early online date | 7 Sept 2018 |
| DOIs | |
| Publication status | Published - Dec 2018 |
Keywords
- Letter
- Kidney Neoplasms/drug therapy
- Nephrology/standards
- Ipilimumab/adverse effects
- Humans
- Nivolumab/adverse effects
- Treatment Outcome
- Drug Approval
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Patient Selection
- Evidence-Based Medicine/standards
- Clinical Decision-Making
- Carcinoma, Renal Cell/drug therapy
- Urology/standards
- Antineoplastic Agents, Immunological/adverse effects
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: European Urology, Vol. 74, No. 6, 12.2018, p. 849-851.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition
T2 - The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
AU - Bex, Axel
AU - Albiges, Laurence
AU - Staehler, Michael
AU - Bensalah, Karim
AU - Giles, Rachel H
AU - Dabestani, Saeed
AU - Hofmann, Fabian
AU - Hora, Milan
AU - Kuczyk, Markus A
AU - Lam, Thomas B
AU - Marconi, Lorenzo
AU - Merseburger, Axel S
AU - Fernández-Pello, Sergio
AU - Tahbaz, Rana
AU - Abu-Ghanem, Yasmin
AU - Volpe, Alessandro
AU - Ljungberg, Börje
AU - Escudier, Bernard
AU - Powles, Thomas
N1 - Funding Information: Conflicts of interest: Professor Dr. Thomas Powles is a company consultant for Novartis, Pfizer, and GlaxoSmithKline; has received company speaker honoraria from Novartis, Pfizer, GlaxoSmithKline, BMS, MSD, and Genentech; has participated in trials for GlaxoSmithKline, Pfizer, BMS, Genentech, and Genetech; and has received grants/research support from GlaxoSmithKline, Pfizer, and Novartis. Professor Dr. Axel Bex has received company speaker honoraria from Pfizer; has participated in trials for Pfizer Europe; has participated in advisory boards for GlaxoSmithKline and Novartis; is a company consultant for Pfizer and Novartis; and has received grants/research support from Pfizer. Professor Dr. Börje Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has participated in trials for GlaxoSmithKline, Medivation, Pfizer, and Janssen R&D; and has been on advisory boards for Pfizer and GlaxoSmithKline. Professor Dr. B. Escudier has received honorarium from BMS. Professor Dr. Laurence Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and has received research funding from Pfizer and Novartis. Professor Dr. Karim Bensalah has received grants/research support from Pfizer and honoraria or consultation fees from Intuitive Surgical. Professor Dr. Michael Staehler is a company consultant for Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, and Bayer; has received company speaker honoraria from Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, Bayer, and Aveo; has participated in trials for Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, Aveo, Wilex, and Immatics; has received fellowships and travel grants from Pfizer, Novartis, GlaxoSmithKline, Roche, and Bayer; has received grants/research support from Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, and Aveo; and took part in the S-TRAC trial as an investigator and is an author on the S-TRAC publication. Professor Dr. Milan Hora has received company speaker honoraria from Covidien, Olympus, Janssen, and Astellas; has participated in trials for Janssen; and has received grants/research support from Ipsen. Professor Dr. Markus A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, and Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, and Hexal; has received company speaker honoraria from Pfizer, Astellas, Bayer, GlaxoSmithKline, Pierre Fabre, Janssen Cilag, and Hexal; has participated in trials for the ProtecT Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, and Janssen; and has received grants/research support from Wyeth and Pfizer. Dr. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GlaxoSmithKline, Astellas, and Ipsen. Professor Dr. Axel S. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, and Astellas; has received grants/research support from Wyeth; and has participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. Professor Dr. Rachel H. Giles, Professor Dr. Alessandro Volpe, Dr. Saeed Dabestani, Dr. Fabian Hofmann, Dr. Lorenzo Marconi, Dr. Sergio Fernández-Pello, Dr. Rana Tahbaz, and Dr. Yasmin Abu-Ghanem have nothing to disclose.
PY - 2018/12
Y1 - 2018/12
KW - Letter
KW - Kidney Neoplasms/drug therapy
KW - Nephrology/standards
KW - Ipilimumab/adverse effects
KW - Humans
KW - Nivolumab/adverse effects
KW - Treatment Outcome
KW - Drug Approval
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects
KW - Patient Selection
KW - Evidence-Based Medicine/standards
KW - Clinical Decision-Making
KW - Carcinoma, Renal Cell/drug therapy
KW - Urology/standards
KW - Antineoplastic Agents, Immunological/adverse effects
UR - http://www.scopus.com/inward/record.url?scp=85056208512&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2018.08.029
DO - 10.1016/j.eururo.2018.08.029
M3 - Article
C2 - 30201510
SN - 0302-2838
VL - 74
SP - 849
EP - 851
JO - European Urology
JF - European Urology
IS - 6
ER -